Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 235 mg fosnetupitant/0.25 mg palonosetron ); Injection (intravenous; 235 mg fosnetupitant/0.25 mg palonosetron [235 mg/0.25 mg per 20 mL] [11.75 mg/0.0125 mg per mL)]); Capsule (oral; 300 mg netupitant/0.5 mg palonosetron). |
| Drug Class | Substance P/neurokinin-1 (NK-1) receptor antagonists and serotonin-3 (5-HT3) receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Akynzeo capsule is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy
- Akynzeo for injection and Akynzeo injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy
- Akynzeo is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and netupitant or fosnetupitant, substance P/neurokinin-1 (NK-1) receptor antagonists: palonosetron prevents nausea and vomiting during the acute phase and netupitant/fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Highly Emetogenic Chemotherapy (HEC): Fosnetupitant + palonosetron achieved a complete control rate of 810 per 1000 participants (relative risk (RR) 1.15, 95% confidence interval (CI) 0.97 to 1.37, moderate certainty), while aprepitant + granisetron reached 704 per 1000, and netupitant + palonosetron was similar with 704 per 1000 (RR 1.00, 95% CI 0.93 to 1.08, high certainty).
- Moderately Emetogenic Chemotherapy (MEC): Aprepitant + palonosetron had a complete control rate of 716 per 1000 participants (RR 1.29, 95% CI 1.00 to 1.66, low certainty), with rolapitant + granisetron following at 660 per 1000 (RR 1.19, 95% CI 1.06 to 1.33, high certainty).
- Highly Emetogenic Chemotherapy (HEC): Serious adverse events (SAEs) were reported for aprepitant + granisetron at 35 per 1000 participants, with lower SAE rates for fosaprepitant + ondansetron at 8 per 1000 (RR 0.23, 95% CI 0.05 to 1.07, low certainty) and casopitant + ondansetron at 8 per 1000 (RR 0.24, 95% CI 0.04 to 1.39, low certainty).
- Moderately Emetogenic Chemotherapy (MEC): SAEs occurred in 153 of 1000 participants receiving granisetron, with a slightly higher rate in those on rolapitant + granisetron at 176 per 1000 (RR 1.15, 95% CI 0.88 to 1.50, low certainty).
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Akynzeo (netupitant and palonosetron) Prescribing Information. | 2023 | Helsinn Therapeutics (U.S.), Inc., Iselin, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis | 2021 | The Cochrane Database of Systematic Reviews |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. | 2023 | ESMO Open |
| Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline. | 2022 | Pediatric Blood & Cancer |
| Antiemetics: ASCO Guideline Update. | 2020 | Journal of Clinical Oncology |